Pariet
PreclinicalSmall molecule
EisaiPariet is one of 30 small molecule programs targeting First-line. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
18 competitors in Duodenal Ulcer
#DrugCompanyPhaseTrials
1Aleve
Jazz PharmaceuticalsApproved
Cytotec
PfizerApproved
Bayer Aspirin
BayerApproved
Biaxin
AbbVieApproved
Voltaren
NovartisApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Doryx
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Potassium Iodide
MMeda Pharmaceuticals
Approved
Advil
KKenvue Brands
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Duodenal Ulcer1 trial
TED1 trial
First-line1 trial
Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment
Completed·—·N/A·NCT05152004·240 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pariet. EMBL-EBI & Wellcome Sanger Institute.
- [4]